HCA Healthcare (HCA) reported $18.32 billion in revenue for the quarter ended March 2025, representing a year-over-year increase of 5.7%. EPS of $6.45 for the same period compares to $5.36 a year ago.The reported revenue represents a surprise of +0.08% over the Zacks Consensus Estimate of $18.31 billion. With the consensus EPS estimate being $5.77, the EPS surprise was +11.79%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determi ...

Group 1 - HCA Healthcare reported quarterly earnings of $6.45 per share, exceeding the Zacks Consensus Estimate of $5.77 per share, and up from $5.36 per share a year ago, representing an earnings surprise of 11.79% [1] - The company posted revenues of $18.32 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.08%, and an increase from $17.34 billion year-over-year [2] - HCA shares have increased approximately 13.8% since the beginning of the year, contrasting with the S&P 500's decline of -6.8% [3] Group 2 - The current consensus EPS estimate for the upcoming quarter is $6.18 on revenues of $18.45 billion, and for the current fiscal year, it is $24.98 on revenues of $74.69 billion [7] - The Medical - Hospital industry, to which HCA belongs, is currently ranked in the top 10% of over 250 Zacks industries, indicating strong performance potential [8] Group 3 - HCA has surpassed consensus EPS estimates in all four of the last quarters, indicating consistent performance [2] - The estimate revisions trend for HCA is currently mixed, resulting in a Zacks Rank 3 (Hold) for the stock, suggesting it is expected to perform in line with the market in the near future [6]

HCA Healthcare delivered a strong first quarter, beating expectations in both earnings and revenue.HCA Healthcare (HCA 1.64%), a prominent player in the healthcare sector, announced robust first-quarter results for 2025 on Friday, April 25, that surpassed market expectations. The company recorded an adjusted EPS of $6.45 for Q1 2025, exceeding the anticipated $5.75. Its reported revenue was $18.32 billion, slightly above the expected $18.26 billion.MetricQ1 2025Analysts' EstimateQ1 2024Change (YOY)Adjusted ...

Exhibit 99.1 For the first quarter of 2025, Adjusted EBITDA totaled $3.733 billion, compared to $3.353 billion in the first quarter of 2024. Adjusted EBITDA is a non-GAAP financial measure. A table providing supplemental information on Adjusted EBITDA and reconciling net income attributable to HCA Healthcare, Inc. to Adjusted EBITDA is included in this release. Same facility admissions increased 2.6 percent and same facility equivalent admissions increased 2.8 percent in the first quarter of 2025, compared ...

Due to the essentiality of healthcare, the medical sector can provide a defensive hedge against market uncertainty, and investors may be eyeing AbbVie (ABBV)  and HCA Healthcare (HCA)  stock ahead of their Q1 reports on Friday, April 25.Being the largest non-governmental operator of acute care hospitals in the United States, HCA shares are up a very respectable +11% year to date, with pharmaceutical giant AbbVie’s stock virtually flat but outperforming the benchmark S&P 500’s 10% decline as well. That said, ...

Group 1: Earnings Estimates - HCA Healthcare is expected to report first-quarter 2025 earnings of $5.77 per share on revenues of $18.31 billion, indicating a year-over-year earnings growth of 7.7% and revenue growth of 5.6% [1][2] - For the full year 2025, the revenue estimate is $74.69 billion, reflecting a 5.8% increase year-over-year, while the EPS estimate is $24.98, implying a 13.8% increase year-over-year [2] Group 2: Recent Performance - HCA Healthcare has consistently beaten earnings estimates in the last four quarters, with an average surprise of 5.9% [2] - The company has an Earnings ESP of 0.00% and a Zacks Rank of 3 (Hold), indicating uncertainty regarding an earnings beat for the upcoming quarter [3] Group 3: Operational Metrics - The consensus estimate for equivalent admissions shows a 3.4% year-over-year growth, while the model predicts a 3.5% increase; revenue per equivalent admission is expected to rise by 2% [5] - Equivalent patient days are estimated to grow by 1.8% year-over-year, but rising expenses and lower occupancy rates pose challenges [6] Group 4: Expense and Occupancy Trends - Total operating expenses are projected to increase by 5.8% year-over-year, driven by higher salaries, benefits, and supply costs, with supply costs expected to rise nearly 8% [7] - The occupancy rate is estimated at 72.68%, down from 75.20% a year ago, and the average length of stay is expected to decline by 2.4% [7]

Core Insights - HCA Healthcare is expected to report quarterly earnings of $5.77 per share, reflecting a year-over-year increase of 7.7% and revenues of $18.31 billion, up 5.6% from the previous year [1] Earnings Estimates - There have been no revisions in the consensus EPS estimate over the last 30 days, indicating stability in analysts' forecasts [1][2] Key Metrics Projections - Revenue per Equivalent Admission is projected to reach $18,026.95, compared to $17,666 in the same quarter last year [4] - Equivalent Admissions are estimated at 1.02 billion, up from 981.52 million year-over-year [4] - Admissions are expected to total 579.28 million, an increase from 560.87 million [5] - Equivalent Patient Days are projected at 4.96 million, compared to 4.87 million last year [5] - Average Length of Stay is expected to remain at 5 days, consistent with the previous year [5] - The Number of hospitals is projected to increase to 191 from 188 [6] - Inpatient Revenue per Admission is estimated at $19,580.02, up from $18,923 in the same quarter last year [6] - Licensed Beds at End of Period are expected to reach 50,132, compared to 49,724 last year [7] - Patient Days are projected at 2,817.09, up from 2,781.6 days year-over-year [7] - The Number of freestanding outpatient surgery centers is expected to be 124, compared to 121 last year [8] Stock Performance - Over the past month, HCA shares have recorded a return of -4.9%, while the Zacks S&P 500 composite has seen a decline of -8.9% [8]

Core Insights - The article discusses an investment service and community focused on the oil and natural gas sector, emphasizing cash flow and the potential for value and growth in this industry [1]. Group 1: Investment Service Features - The service offers subscribers access to a model account with over 50 stocks, detailed cash flow analyses of exploration and production (E&P) firms, and live chat discussions about the sector [2]. - A promotional offer is available for a two-week free trial, encouraging new users to explore opportunities in the oil and gas market [3].

Three major U.S. indexes the Nasdaq Composite, the S&P 500 and the Dow Jones Industrial Average closed deeply in red by 9.89%, 9.58% and 8.78% respectively, last week. The stocks have taken a beating after the implementation of President Donald Trump’s reciprocal tariff policies with major trading partners on April 2, 2025. Uncertainty over the impact of such policies on the U.S. economy has stoked fear of a near-term recession among market participants.Analysts are expecting a slowdown in economic growth a ...

Market Overview - Wall Street experienced significant losses, with the Dow recording back-to-back losses exceeding 1,500 points on April 3 and 4, including a drop of 2,231 points on April 4, marking one of the highest single-day declines in history [4] - The S&P 500 index fell more than 10% over the last two trading days of the previous week, with a 6% drop on April 6, its worst day since March 2020, currently in correction territory with a 17% decline from its February peak [5] - The Nasdaq Composite also plummeted 6% on each of the last two trading days, now in bear territory with a 22% drop from its recent high, while the CBOE VIX reached 45 on April 4, indicating extreme market fear [6] Defensive Stocks Recommendations - Investing in defensive sectors such as consumer staples, utilities, and healthcare is recommended, with five stocks identified: Molson Coors Beverage Co. (TAP), CenterPoint Energy Inc. (CNP), WEC Energy Group Inc. (WEC), Abbott Laboratories (ABT), and HCA Healthcare Inc. (HCA) [3][7] Company Insights Molson Coors Beverage Co. (TAP) - TAP has shown strong performance in Canada and EMEA&APAC, with Q4 2024 results surpassing estimates and year-over-year earnings growth [11] - Projected sales growth for 2025 is in low-single digits, with underlying EPS expected to grow in high-single digits [12] - Current revenue and earnings growth rates are 0.1% and 6.9%, respectively, with a dividend yield of 3.07% [13] CenterPoint Energy Inc. (CNP) - CNP is positioned to benefit from rising electricity demand due to the electrification of transportation and investments in renewable energy [14] - The company is investing in infrastructure to support electric vehicle (EV) growth, including off-road electrification initiatives [16] - Expected revenue and earnings growth rates for the current year are 3.2% and 8%, respectively, with a dividend yield of 2.44% [17] WEC Energy Group Inc. (WEC) - WEC is benefiting from both organic and inorganic growth, with strategic investments aimed at enhancing infrastructure and achieving net carbon neutrality by 2050 [18] - Demand from commercial and residential customers is improving, with expected revenue growth in the 2025-2027 period [19] - Current revenue and earnings growth rates are 9.2% and 8.5%, respectively, with a dividend yield of 3.42% [20] Abbott Laboratories (ABT) - ABT utilizes AI for healthcare solutions, including advanced medical imaging and predictive algorithms for heart attack prevention [21] - The company holds a strong position in point-of-care testing across various health areas [22] - Expected revenue and earnings growth rates for the current year are 5.9% and 10.3%, respectively, with a dividend yield of 1.90% [23] HCA Healthcare Inc. (HCA) - HCA's revenues are increasing due to growth in admissions and surgeries, with projected revenues for 2025 between $72.8 billion and $75.8 billion, indicating a 5.2% rise from 2024 [24] - The company has benefited from acquisitions and its telemedicine business, with operating cash flows rising 11.5% year over year in 2024 [25] - Expected revenue and earnings growth rates for the current year are 5.8% and 13.8%, respectively, with a dividend yield of 0.87% [25]